AN2 Therapeutics Q2 Loss Widens to $8.2M on Higher R&D; Cash Runway into 2029
ANTX has more than doubled off its 52-week low of $1 on light trading volume (0.2× avg).
Summary
AN2 Therapeutics reported a Q2 net loss of $8.19 million, or $0.18 per share, widening from the prior year on increased R&D spending tied to advancing three Phase 2 programs. The company ended the quarter with $79.9 million in cash, which it expects to fund operations into 2029. Pipeline catalysts include a Phase 2 chronic Chagas disease trial starting late 2026, enrollment in a global Phase 2 polycythemia vera trial in Q4 2026, and a second boron-based candidate by year-end. The loss and spending ramp are in line with a pre-revenue biotech scaling clinical activity, but the cash position provides a long runway to reach key data readouts.
At the time of this announcement, ANTX was trading at $5.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $211.4M. The 52-week trading range was $1.00 to $6.91. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.